PFE Trading Analysis - 10/23/2026 05:01 PM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge headlines and context for Pfizer (PFE) that may relate to the current data picture:

• Pfizer announced positive Phase 3 trial results for an updated respiratory virus vaccine candidate earlier in October 2026, supporting sentiment in the healthcare sector.
• The company confirmed its quarterly dividend of $0.43 per share with an ex-dividend date of November 6, 2026, reflected in the fundamentals data.
• Management reiterated full-year guidance during an investor call, noting cost-discipline efforts amid patent-cliff concerns.
• Broad pharmaceutical stocks saw moderate bid after softer-than-expected inflation data, potentially aiding PFE's push to 52-week highs.
• No major negative regulatory action or lawsuit escalation reported recently; news flow has been largely neutral-to-positive.

Context: The constructive news backdrop aligns with the stock's recent advance to the $30.00 area and rising options call dollar volume, though embedded sentiment shows a balanced read rather than euphoria.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for PFE:

• Trailing P/E: 39.60; Trailing EPS: $0.76 — elevated multiple versus many large-cap peers, with no forward P/E (null) or PEG (null) provided for relative growth-adjusted comparison.
• Market Cap: $171,161,210,220; Shares Outstanding: 5,699,674,000; Institutional Ownership: 44.41%.
• Dividend Yield: 5.71%; Dividend Rate: $1.72; Ex-Dividend Date: 2026-11-06 — attractive income profile.
• Beta: 0.15 — very low market sensitivity; Historical Volatility: 16.19%.
• 52-Week High: $30.25; 52-Week Low: $23.62 — current price near the top of the annual range.
• Revenue growth, gross/operating/net margins, ROE, Debt/Equity, and Free Cash Flow are null in the data — not available for assessment.
• Analyst consensus, target mean price, and number of opinions are null — no street target context embedded.

Fundamentals show a low-beta, high-yield large-cap trading near 52-week highs with a rich trailing P/E. This diverges from the strongly bullish technical momentum (RSI 79.86) but aligns with the stable, defensive nature implied by low beta.

Current Market Position

Current price per indicators: $30.06 (2026-10-23 close: $30.06). Recent daily action shows a rally from $27.12 (30-day low on 2026-10-05) to $30.44 (30-day high on 2026-10-22), with a slight pullback to $30.06 on 2026-10-23.

Minute bars (2026-10-22 to 2026-10-23 15:55) show opening around $30.05, intraday high $30.44 on 10-22, and final prints easing to $30.03 by 15:55 on 10-23 with a volume spike of 828,511 at the last bar — marginal late-session weakness.

Technical Analysis

SMA alignment: Price ($30.06) > SMA5 ($29.99) > SMA20 ($28.79) > SMA50 ($28.30) — bullish stack with no bearish crossover. RSI 14 at 79.86 indicates overbought momentum. MACD histogram positive (0.12) confirms bullish bias. Bollinger upper at $30.60; price is near upper band but not beyond. 30-day range: high $30.44, low $27.12 — price at ~96th percentile of range.

True Sentiment Analysis (Delta 40-60 Options)

Options flow via True Sentiment (Delta 40-60 only):

Call Volume: $1,057,513 (55.0%) Put Volume: $864,129 (45.0%) Total: $1,921,642

Sentiment: Balanced. Call contracts 10,995 vs put 9,164; 27 call trades vs 29 put trades. Pure directional conviction is modestly call-leaning but not dominant. This balanced read diverges from the overbought RSI and strong SMA bullishness — suggesting upside may be tentative near resistance.

Key Price Levels (Observational Only)